| HS Code | 840988 |
| Iupac Name | (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol |
| Molecular Formula | C19H16FNO |
| Cas Number | 1436576-22-9 |
| Appearance | White to off-white solid |
| Smiles | C1CC1C2=NC=C(C=C3C=CC(=CC3=C2)C4=CC=C(C=C4)F)CO |
| Pubchem Cid | 91857903 |
| Solubility | Slightly soluble in organic solvents |
| Logp | Estimated ~3.5 |
| Storage Conditions | Store at 2-8°C, away from light and moisture |
| Chemical Class | Quinoline derivative |
As an accredited (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Amber glass bottle containing 5 grams of (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol, sealed with a screw cap and labeled. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol involves secure drum packaging and moisture protection. |
| Shipping | The chemical (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol will be shipped in a tightly sealed, inert container, clearly labeled with hazard information. It will be packed according to standard chemical safety regulations, protected from light, heat, and moisture, and accompanied by a safety data sheet and proper transport documentation. |
| Storage | Store **(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol** in a tightly sealed container, protected from light and moisture, at 2-8°C (refrigerator). Keep away from sources of ignition, strong acids, and oxidizing agents. Ensure good ventilation in the storage area. Label the container clearly and handle only in a chemical fume hood while wearing appropriate personal protective equipment (PPE). |
| Shelf Life | Shelf life: Stable for at least 2 years when stored tightly sealed at 2–8 °C, protected from light and moisture. |
(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol has emerged as a crucial intermediate for several specialized sectors within the pharmaceutical and fine chemical industries. As the original manufacturer, we supply this compound with high assay and strict traceability, enabling integration into controlled industrial formulations where regulatory precision and batch consistency remain paramount. Below, we detail primary industrial uses, highlighting the specific compliance environment, proven formulation benchmarks, insertion points in downstream synthesis, and the distinctive finished good lines that rely on this high-value material.
Leading pharmaceutical producers utilize this compound as a core building block in multi-step synthesis pathways for kinase inhibitor drug candidates, particularly in oncology and immunology research pipelines. Its quinoline core and structural modifications streamline selective inhibitor design, reducing steps in late-stage functionalization and supporting robust impurity profiling during scale-up campaigns. Integration typically focuses on pilot and commercial production scales under documented quality oversight.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Exploratory R&D and commercial producers synthesize CNS-active pharmaceuticals by leveraging this material's fluorinated quinoline motif, which optimizes blood-brain barrier penetration and enhances metabolic stability. Its structure enables precise functionalization in the key medicinal chemistry steps used for next-generation neuropsychiatric small molecules and nootropic agent development, supporting rigorous stereochemical control from pilot to commercial batch production.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
In the crop protection and agrochemical discovery sector, screening programs deploy this compound as a rigid scaffold for designing new insecticidal and fungicidal actives. Its combination of cyclopropyl and fluorophenyl moieties bolsters environmental stability and activity spectra in prototype formulations, meeting regulatory dossier requirements for structure-activity relationship elucidation and impurity mapping within advanced agricultural chemical research pipelines.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Providers of screening compound libraries and specialty fine chemical firms use this substance in combinatorial synthesis campaigns for high-value fluorinated quinoline analogs. The structural features enable diverse functionalization, supporting SAR library assembly for contract research organizations (CROs) and custom synthesis offerings under quality-controlled, traceable supply chains.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Life in the lab moves fast. Trends shift, markets hurry, yet nothing replaces doing chemistry right, batch after batch. Here, producing (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol stands as a regular part of our work. Though the molecular name sounds like a mouthful, the process behind it follows a rhythm familiar to anyone who has spent years in synthesis: measured steps, strict controls, and an eye for minor signs only experience can teach.
Synthesis starts with building the core quinoline structure, which leads us through chlorination, cyclopropyl coupling, and installation of a fluorophenyl group. The methyl alcohol function lands last, often through careful reduction, its position vital for bioactivity in testing downstream. The equipment hums through the routine, but even a tiny deviation—moisture sneaking into a flask, a half-degree shift on the thermometer—can push impurity profiles out of spec. Those deviations never look catastrophic, but purification doesn't grow easier with shortcuts.
Our batches rarely look identical to each other under close inspection, and for good reason: (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol attracts formulation projects where trace byproducts can disrupt everything downstream. Impurities creep into analytical readouts, amplify backgrounds in NMR, and muddy results in applications research. Chemists building combinatorial libraries report these headaches more than anyone. Without clean product, every screen picks up signals that shouldn’t be there.
In my early days, pulling a batch off during a heatwave, we faced slight yellowing by the time the rotavap finished. The crude solid had a faint odor, almost medicinal—tiny hints of side reactions. Standard silica column couldn’t pull the last traces apart. Over years, we iterated through changes—switching solvents, timing the reduction with sharper endpoint checks, and improving vacuum-drying protocols. That detail work sets solid manufacturers apart from resellers shuffling bulk stock. Each tweak came from reviewing chromatograms late at night, adjusting, then waking up thinking, “Let’s do another run and see.” The lesson stuck: clear communication between staff, close analytical controls, and plenty of patience beat any shortcut.
Our current product specification for (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol arose from years of test runs. Water content lands under 0.1 percent by Karl Fischer. Single main peak noted by both HPLC and proton NMR, matching spectral fingerprint charts stored since our first successful batch. Melting point remains consistent within two degrees centigrade, signaling that the fluorophenyl and cyclopropyl rings orient as expected in the crystal lattice.
Batch records live on paper, but memories of stubborn filtration runs and unexpected precipitates shape every step we enforce. Whether a kilo is meant for medicinal chemistry groups or a few grams shipped to a research pilot plant, we hand-inspect color and granularity after drying. We have faced requests for custom particle size—usually for specialized dissolution studies—but the chemistry itself leaves little room for fancy granularity until you grind, sieve, and check again.
This compound often leaves our doors headed for early-stage pharma programs—usually hostile territory for contaminants. Some teams study kinase inhibition or related pathways, attracted by the fluorine’s effect on stability and the cyclopropyl offering resistance to metabolic breakdown. That role means every microgram counts for screening. Researchers don’t want side peaks as false positives or unexpected color interfering in a plate reader assay.
We took calls from groups working with automation platforms—those demand repeated quality across different lots. The first few transfers, pipettes clogged up from unseen fibers or microcrusts left behind in poorly finished product. After feedback, we moved to stainless steel spatulas and counter-checked product by laser scattering before packing. Long hours spent customizing our final handling meant those downstream users could trust both the weight on the scale and the clarity on their results files.
Not every customer sends thanks, but the best validation has come from those returning a year later, requesting the “same batch quality as last time.” We keep samples frozen, ready for side-by-side comparison—a process as routine as our daily solvent checks.
Having compared our (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol to variants lacking the fluorine or the cyclopropyl ring, we find differences both in synthetic ease and downstream properties. Removing fluorine would spare steps and reduce cost, but customers mention increased degradation in light and heat exposure. Control studies prove the F group gives longer shelf life without annoying byproducts—especially valuable for groups cycling through months-long trials.
Quinoline analogs without cyclopropyl show altered solubility. Some dissolve easier, at the expense of metabolic stability—a tradeoff too steep for groups chasing selectivity in preclinical screens. The cyclopropyl ring introduces steric hindrance, benefiting those after persistent biological activity. In several research consortia, chemists have shown greater retention in cell-based assays. We picked that up as anecdote, confirmed in off-take testing, and have since found downstream customers see it echoed in long-term stores.
Armed with this feedback, we shifted to tighter control of ring-forming steps. Analytical chemists reminded us that correct integration under the NMR peaks ties directly to reliable characterization—a lesson learned from a month chasing a misassigned impurity. An error in the cyclopropyl coupling produced an almost invisible peak, detectable as a ghost in longer runs. That batch reinforced the need for proper headspace management during the ring closure; slight variation led to partial epimerization, changing how the compound responded to acid treatment downstream.
Each season brings its quirks—humidity swings alter crystallization, local water supply chemistry shifts yield. Early summer rains once drove up our isolated yields, but invisible dissolved gases caused foaming during precipitation. We adapted by shifting sequence order, finishing batches before dew point swings could introduce water into any column. That year, only by running chromatograms compared to archived samples did we catch a subtle new impurity introduced during filtration—a lesson that brought us to weigh filter paper as carefully as any flask.
Polishing product before filling drummed into us the reality that chemical manufacturing demands vigilance on both big and small changes. Sourcing a new solvent drum—despite matching all standard documentation—still required on-line validation of absence of leachable plasticizers. A change in supplier had us pausing mid-batch, not out of regulation, but from genuine readiness to avoid end-customer headaches. Again, no shortcut replaces strong internal standards built by iteration and proof.
Routine doesn’t mean complacency. Every new account brings another specification, and requests keep us honest. One pharma client insisted on a batch-specific mass spectrum, confirming absence of sodium adducts. Their request led us to run two calibration curves side by side for every process, and, learning from the challenge, we eventually improved all internal mass spectrometry practices. That kind of customer-driven iteration translates into tighter impurity control, benefiting every subsequent shipment.
Every manufacturer faces disruptions, from logistics to raw material lag. The quinoline starting material’s price doubled during a global supply pinch, yet we refused to substitute alternative grades, even as resellers on the sidelines turned around lower-cost, lower-spec batches. By paying the premium and holding the line, we kept customer responses direct and transparent. End users reported no change in bioassay outcomes, a point of pride for our process team.
On another front, regulatory frameworks around trace solvents have tightened. Our site runs regular GC-headspace analyses—not only to meet laws, but from lived experience correcting a methyl chloride residual that once crept above comfort levels. Colleagues remember the cleanup, the repeated distillations over activated charcoal. Rather than waiting for external audits, we keep the practice embedded in our weekly cycle, and no longer accept “close is good enough” from any supplier.
Too many market players cut, blend, or rename bulk chemicals. Our methods grew from walking the shop floor, running test columns, improving process controls south of what outside consultants recommend. Every time a new TLC stain pattern shows up, our team cross-checks solvent sources, verifies packing densities, and updates both our own and customer records.
For us, process transparency sits in the records, not just the paperwork. Storage sealed under argon, use of color-indicating desiccants, and monitoring for micro-particle contamination—these measures grow from repeating batches, re-analyzing archived samples, and communicating failures as loudly as successes. Customers who bring us back repeat work do so based on trust forged through these open explanations, not just the certificate inside the box.
We have sat in meetings where stakeholders question why the NMR spectrum contains a faint triplet ten times weaker than main peaks. Instead of deflecting, we pull archived spectra, trace the origin, and resolve the source—sometimes a lingering column impurity, sometimes air introduced by a faulty fitting. Improvements never come from denying the issue, always from chasing it down, root and all.
Side-by-side analysis with other suppliers reveals marked differences. We’ve seen off-patent material with higher background fluorescence, inconspicuous by documentation alone, but strongly pronounced under sensitive detection. These physical cues, missed by samples repackaged or transferred across borders multiple times, show up quickly when you’ve run repeat batches under tightly watched conditions.
Makers aiming for scale often lose sight of minute inconsistencies—those that shape outcomes for researchers, not just bulk analytics. Reports circle back to us about failed API experiments using side-sourced product. In nearly every case, simple GC-MS or an extended-release assay shows the signature of poor control at the point of manufacture. Responding to these, our own teams commit to continuous sample retention, batch record archiving, and regular third-party blind testing.
We hold monthly “failure reviews,” pulling both successful and out-of-spec batches from cold storage. These sessions alone help us drill down root causes; sometimes uncovering subtle shipping contamination, sometimes old raw material ingress. This rugged routine enables quick resolutions to client concerns, nurturing relationships not based on price alone, but on long-evolved expertise supporting the research they aim to achieve.
Producing (2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methanol at this level of detail means all staff—from synthesis to shipping—share a common goal: ensuring researchers receive a tool as close to theoretical expectations as current chemistry allows. We aren’t a warehouse moving things from port to port. Our business depends on perfecting the steps between raw material checks to final envelope seals.
Years in the trenches shape how we see each batch. Careful temperature profiles, degassing, regular calibration of analytics—these habits shape outcomes as much as the published procedures. Chemical manufacturing, especially in specialized pharma-grade compounds, remains less about speed and more about reliably delivering small-batch excellence. Reality tests us in every run; real improvement comes from accepting that, not hiding from it.
It’s easy to look at a list of specifications and assume all material marked “analytical grade” matches your needs. Experience in the workshop teaches otherwise. Analysts at companies large and small deserve to know how each product reached their bench. Product isn’t just what you see in the vial, but the accumulated knowledge and integrity that comes with it, built by continuous review and the will to admit and address flaws, every time.
Standards shift. Requirements grow. Through all changes, quality compounds grow from a foundation rooted in careful work, repeatable controls, and the respect for every researcher counting on results they can trust.